GSK plc (LON: GSK)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 70.21B |
| Revenue (ttm) | 30.33B |
| Net Income (ttm) | 4.93B |
| Shares Out | 4.14B |
| EPS (ttm) | 1.21 |
| PE Ratio | 15.86 |
| Forward PE | 10.46 |
| Dividend | 0.59 (3.41%) |
| Ex-Dividend Date | May 16, 2024 |
| Volume | 1,325,562 |
| Open | 1,733.00 |
| Previous Close | 1,728.50 |
| Day's Range | 1,718.00 - 1,743.00 |
| 52-Week Range | 1,302.60 - 1,743.00 |
| Beta | 0.27 |
| Analysts | n/a |
| Price Target | 212,825.00 (+12,202.02%) |
| Earnings Date | May 1, 2024 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, an increase of 0.14%.
Financial StatementsNews
5 best blue chip stocks to invest in for sustainable gains in May – excluding Apple Inc. (AAPL)
Yesterday, the biggest company in the world in terms of market cap reported its latest earnings. But Apple Inc. is far from the only blue chip stock around.
Senator slams drugmaker for seeming to skirt pledge to cap inhaler cost
Drug manufacturing giant GlaxoSmithKline (GSK) is subverting its pledge to lower the price of its brand-name inhaler products, a key Democratic senator alleged. In a letter to CEO Emma Walmsley made p...
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Inge...
Q1 2024 GSK plc Earnings Call Transcript
Q1 2024 GSK plc Earnings Call Transcript
I'm 'very well paid', says Glaxo boss Emma Walmsley
Dame Emma Walmsley (pictured), who earned £12.7m in 2023, said she felt 'really good' about ithe drugs giant's ability to retain talent.
Senator slams GlaxoSmithKline over cost of asthma inhalers
Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow.
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE: GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2...
GSK raises profit guidance as vaccine demand grows
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.
GSK ups 2024 guidance as HIV drugs and new vaccines boost its bottom line
The British drugmaker’s remaining 4.2% stake in its consumer health arm Haleon also boosted its bottom line, following its spin off in July 2022
GSK Expects Higher Profits Boosted By Vaccines, Asthma Drugs
GSK Plc raised its profit forecast for the year as it predicts higher-than-expected sales from HIV, infectious diseases and respiratory drugs.
GSK Non-GAAP EPS of 43.10p, revenue of £7.4B; updates FY24 outlook
GSK Upgrades Targets as Core Profits Jump
GSK lifted its full-year guidance after first-quarter core earnings rose 28%, helped by higher sales of vaccines and specialty medicines .
GSK raises full-year profit forecast
GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines.
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo...
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'
WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting indu...
GSK Q1 2024 Earnings Preview
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1...
GSK readies for pivotal ruling in Zantac cases
Judge to decide on admission of evidence as part of litigation that has knocked billions off pharma group’s value
Save the Children, GSK launch $1m project to tackle barriers against children immunization in Nigeria, Ethiopia
Ahead of World Immunization Week, Save the Children and GSK have launched a new $1 million initiative to empower local organisations in Nigeria and Ethiopia and fast-track cutting-edge solutions to......
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve...
GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve
GSK faces challenges with its weaker pipeline, but its strong revenue growth and product mix offer potential in catching up to competitors. Read more here.
GSK shingles vaccine shown 82% effective 11 years after vaccination
GSK (GSK) said studies showed that its top-selling shingles vaccine, Shingrix, had an 82% efficacy rate 11 years after vaccination in people aged 50 and older. Read more here.
In Bridgerton and Flonase Collaboration, Both Love and Allergies Are in Bloom
Season 3 of Shonda Rhimes' hit Netflix series Bridgerton focuses on the relationship between Colin Bridgerton and Penelope Featherington, a pairing fans have dubbed "Polin." Inspired by the similarity...
GSK says efficacy of its shingles vaccine remains high after years
British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccina...